Stillwater: Community development director is hired
Zimmerman, who has served as the city's part-time interim community development director since February, has been hired for the permanent position.
He will be transitioning to the new position during the rest of July and August and will start full-time Sept. 2. His salary will be $158,538.
Zimmerman, 52, of Minneapolis, has worked as a planner for HKGi since January 2024. He previously worked as the planning manager and as a planner for Golden Valley.
Stillwater City Administrator Joe Kohlmann said Zimmerman impressed officials with his 'can-do attitude' and ability to 'address issues head-on.'
'Jason is an articulate professional who has demonstrated a strong commitment to the betterment of Stillwater,' Kohlmann said. 'He gets along very well with coworkers, elected officials, and members of the public.'
Zimmerman grew up in Waconia, Minn., a rural community west of Minneapolis, and said 'Stillwater has that same small-town feel, but with an oversized impact on the surrounding area due to its history and draw for visitors.'
'I'm looking forward to helping capture that enthusiasm and sense of pride as we work to update and improve policies, procedures, and a shared vision for the future,' he said. 'Stillwater seems poised to cement itself as a premiere city, and I'm excited to be a part of that.'
Zimmerman has a master's degree in city planning from the Massachusetts Institute of Technology and a bachelor's degree in economics from Carleton College.
In his spare time, he enjoys running ultra-marathons — '50 miles, 100 miles and even some that are over 100 miles,' he said. 'The longest distance I've ever run at one time is 180 miles. That was in Moab, Utah. That took a little more than four days. There was some sleep sprinkled in there.'
He and his wife, Amie DeHarpporte, have four children and numerous household pets.
Tim Gladhill, who previously held the position, left Stillwater in August 2024 to become community development director in Brooklyn Park.
Danette Parr, the community development director in Maplewood, was hired in November to do the job; she resigned effective Dec. 31. Parr, who returned to her job in Maplewood, said Monday that Stillwater 'wasn't the fit (she) was looking for and, unfortunately, sometimes you just don't know that until you get there.'
Related Articles
Stillwater cracks down on use of e-moto bikes on city trails
After spending decades as an actor, Reed Sigmund tries his hand at directing
Stillwater installs cameras, license-plate readers to deter crime
Stillwater: Silver Sobriety marks 10 years with new location, new executive director
St. Croix River bridge inspection underway; delays expected
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
Bio-Techne Announces Exosome Diagnostics Divestiture
MINNEAPOLIS, Aug. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced an agreement where Mdxhealth SA will acquire its Exosome Diagnostics Inc. business, including the ExoDx Prostate (EPI) test, CLIA-certified clinical laboratory and related assets. Bio-Techne will retain access to the proprietary exosome-based technology for ongoing kit development in its precision diagnostics growth pillar. "Mdxhealth is the ideal acquirer of our ExoDx Prostate test and CLIA-certified laboratory," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "Mdxhealth has made several strategic moves over the past few years to position the company as a leader in urology and prostate cancer diagnostics. The addition of ExoDx Prostate to their portfolio accelerates their leadership in this market." Kelderman continued, "Following this transaction, Bio-Techne will strengthen its foundation as a developer of innovative, high value, high margin products, tools and reagents for the life science research and clinical diagnostics markets. This repositioning of the portfolio enables Bio-Techne to direct additional investments to further strengthen this foundation, while creating an immediate uplift to our sector leading operating margin profile." "ExoDx Prostate is a strong strategic fit with our rapidly growing urology and prostate cancer diagnostic business," said Michael McGarrity, Chief Executive Officer of Mdxhealth. "The ExoDx Prostate test equips men with information to make better decisions and avoid unnecessary and potentially dangerous prostate biopsies. Bio-Techne has done a tremendous job delivering this necessary information to patients and growing the base of physicians leveraging this tool. We are looking forward to building on this success." Under the terms of the agreement, Bio-Techne will receive $5 million in MDXH stock combined with future considerations. The transaction is expected to be completed during the first quarter of Bio-Techne's fiscal 2026. Bio-Techne will discuss this transaction, as well as its fourth quarter fiscal 2025 performance on its earnings call tomorrow, August 6th, 2025, at 8:00 a.m. CDT. To listen, please dial 1-800-274-8461 or 1-203-518-9814 (for international callers), and reference conference ID: TECHQ4. The earnings call can also be accessed via webcast through the following link Forward Looking Statements: Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward looking statements in this press release include statements regarding our belief about the impact of our pending divestiture of Exosome Diagnostics Inc. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships. For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements. About Bio-TechneBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has over 3,000 employees worldwide. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate About mdxhealth®Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers and prognosis of recurrence risk. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and U.S. headquarters and laboratory operations based in Irvine, California, with additional laboratory operations in Plano, Texas. For more information, visit and follow us on social media at: and For more information:info@ LifeSci Advisors (IR & PR)John FrauncesManaging DirectorTel: +1 917 355 2395Jfraunces@ ir@ View original content to download multimedia: SOURCE Bio-Techne Corporation
Yahoo
2 hours ago
- Yahoo
As UnitedHealth's troubles mount, new CFO faces challenge to restore confidence
Good morning. We're in the second half of 2025, and CFO turnover continues. This time, it's at embattled UnitedHealth Group—ranked No. 3 on the Fortune 500 and the largest U.S. health care company by revenue in 2024. John F. Rex, who joined the company in 2012 and has served as CFO since 2016, is being replaced—not by an internal candidate, but by an external hire. Rex will become a strategic advisor to the CEO, Stephen J. Hemsley. Wayne S. DeVeydt, most recently a managing director and operating partner at Bain Capital, will assume the CFO role effective Sept. 2. DeVeydt brings experience in operational improvement and growth acceleration—a skill set that will be valuable as UnitedHealth's share price is down more than 50% over the past year. The leadership change comes on the heels of a troubling Q2 2025, in which UnitedHealth's financial results fell far short of Wall Street expectations, further rattling investors. The company shocked markets on July 29 by reporting unexpectedly weak quarterly results, according to Fortune's Geoff Colvin. As Colvin writes: 'The crisis first manifested in April. UnitedHealth Group was emerging from the trauma of executive Brian Thompson's high-profile murder in December when the company released first-quarter profits far below Wall Street's expectations. The stock plunged, slashing over $100 billion from market value within hours. A month later, CEO Andrew Witty abruptly resigned for unspecified personal reasons, and former CEO Stephen Hemsley returned to the job. The stock plummeted again.' (You can read the complete report here.) Managing risk and costs Now, DeVeydt—also former chairman and CEO of Surgery Partners and former CFO at Anthem (now Elevance)—will need to play a significant role in steering UnitedHealth back on course. The company has four main segments: UnitedHealthcare (coverage), Optum Health (care delivery), Optum Insight (software and analytics), and Optum Rx (pharmacy benefits). Industry analysts say the road ahead won't be easy. I asked Julie Utterback, senior equity analyst for health care at Morningstar, for her assessment. 'UnitedHealth—and, frankly, the entire managed care organization (MCO) industry—needs to figure out how to balance the current mismatch between rates and medical utilization in their risk-bearing operations,' she told me. This problem spans the U.S. health care system: higher-than-anticipated medical costs with insufficient premium increases began in Medicare Advantage in late 2023, spread to Medicaid in mid-2024, and now pressure individual exchanges and at-risk employer plans, Utterback other words, rising health costs are outpacing premiums, which is hurting profits for insurers like UnitedHealth. On average, the medical cost ratio (the percentage of revenue spent on patient care) among the six MCOs tracked by Morningstar is expected to be more than 450 basis points higher in 2025 than in the prior decade. In addition, UnitedHealth also faces pressures within its Optum Health unit, where, in some arrangements, the firm not only delivers caregiving services but also assumes the risk of managing a patient's overall health, she said. For MCOs to return to target margins, they need to secure better compensation for the risk they assume across the U.S. health care system, she added. Regarding DeVeydt's priorities as CFO, Utterback said finance organizations will continue to emphasize cost controls. Further adoption of AI and other digital tools to improve back-office efficiency will remain a focus, although UnitedHealth has already prioritized such initiatives for several years, she noted. DeVeydt steps into the CFO role next month with a formidable to-do list, and the future of UnitedHealth's financial recovery on the line. Sheryl This story was originally featured on
Yahoo
2 hours ago
- Yahoo
Wheat Falling to Contract Lows on Tuesday
The wheat complex is continuing to pressure things lower on Tuesday, with losses across the three exchanges. CBT futures are down 9 to 10 cents at midday. Kansas City HRW contracts are 11 to 11 ¼ cents lower in the front months. MPLS spring wheat is down 2 to 3 cents at midday. June trade data from Census showed a total of 1.719 MMT of wheat shipped during the month, which was a 4-year high but down 20.42% from last month. More News from Barchart Coffee Prices Rally on Below-Average Rainfall in Brazil Below-Average Rain in Brazil Supports Coffee Prices Is the Corn Market Undervalued? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! Crop Progress data from USDA shows the US winter wheat 86% harvested, with 87% the normal harvest pace. The spring wheat crop was 95% headed, with harvest now at 5% and behind the 9% average. Conditions were listed at 48% gd/ex, down 1%, as the Brugler500 index was stead at 332. The only state to see improvement was ND, up 4, with MN down 1, MT and WA slipping 2, SD falling 7 and ID down 11. A South Korean importer purchased 65,000 MT of wheat from the US in a private deal overnight. The European Commission estimates the 2025/26 soft wheat exports since July 1 at 1.11 MMT as of 8/3, compared to the 2.64 MMT in the same period last year. Sep 25 CBOT Wheat is at $5.07 1/2, down 9 1/4 cents, Dec 25 CBOT Wheat is at $5.28, down 9 cents, Sep 25 KCBT Wheat is at $5.05 3/4, down 11 1/4 cents, Dec 25 KCBT Wheat is at $5.26 1/2, down 11 cents, Sep 25 MGEX Wheat is at $5.70 3/4, down 2 1/4 cents, Dec 25 MGEX Wheat is at $5.93 1/2, down 2 1/2 cents, On the date of publication, Austin Schroeder did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
